Procaps Group SA (PROC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Procaps Group SA (PROC) has a cash flow conversion efficiency ratio of 1.232x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($47.39 Million) by net assets ($38.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Procaps Group SA worth for the company's overall valuation and market capitalisation.
Procaps Group SA - Cash Flow Conversion Efficiency Trend (2019–2022)
This chart illustrates how Procaps Group SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Procaps Group SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Procaps Group SA ranked by their cash flow conversion efficiency. Explore Procaps Group SA cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sukgyung AT Co. Ltd.
KQ:357550
|
0.047x |
|
Solteam Electronics Co Ltd
TWO:3484
|
0.040x |
|
Bokusgruppen AB
ST:BOKUS
|
-0.040x |
|
CSC Steel Holdings Bhd
KLSE:5094
|
0.004x |
|
Corner Growth Acquisition Corp
NASDAQ:COOL
|
0.000x |
|
Abra Information Technologies
TA:ABRA
|
0.008x |
|
Yieh Hsing Enterprise Co Ltd
TW:2007
|
0.014x |
|
Borosil Scientific
NSE:BOROSCI
|
N/A |
Annual Cash Flow Conversion Efficiency for Procaps Group SA (2019–2022)
The table below shows the annual cash flow conversion efficiency of Procaps Group SA from 2019 to 2022. View latest Procaps Group SA stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $-1.88 Million | $14.11 Million | -7.511x | -672.00% |
| 2021-12-31 | $-38.34 Million | $37.30 Million | -0.973x | -249.39% |
| 2020-12-31 | $-254.68 Million | $70.92 Million | -0.278x | +0.52% |
| 2019-12-31 | $-243.95 Million | $68.29 Million | -0.280x | -- |
About Procaps Group SA
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use… Read more